A randomized trial comparing phosphorylcholine‐coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Internal Medicine

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2796.2004.01398.xPMID 15485474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.

  2004cited by this paper
• A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

  2004cited by this paper
• Heparin-Coated Stent Placement for the Treatment of Stenoses in Small Coronary Arteries of Symptomatic Patients

  2003cited by this paper
• Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

  2003cited by this paper
• Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.

  2002cited by this paper
• Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries.

  2002cited by this paper
• In-stent restenosis in small coronary arteries: impact of strut thickness.

  2002cited by this paper
• Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events: Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial

  2001cited by this paper
• Stent Placement to Prevent Restenosis After Angioplasty in Small Coronary Arteries

  2001cited by this paper
• Stenting for small coronary vessels: a contestable winner.

  2001cited by this paper
• Stent Placement Compared With Balloon Angioplasty for Small Coronary Arteries: In-Hospital and 6-Month Clinical and Angiographic Results

  2001cited by this paper
• Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

  2001cited by this paper
• Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent.

  2001cited by this paper
• Color M-mode Doppler flow propagation velocity in cardiac tamponade: Reply

  2001cited by this paper
• Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells.

  2000cited by this paper
• A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries.

  2000cited by this paper
• A Randomized Trial Comparing Stenting With Balloon Angioplasty in Small Vessels in Patients With Symptomatic Coronary Artery Disease

  2000cited by this paper
• Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries.

  2000cited by this paper
• Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961

  2000cited by this paper
• Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

  1999cited by this paper
• Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

  1999cited by this paper
• Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators.

  1999cited by this paper
• Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

  1999cited by this paper
• Phosphorylcholine coating of ePTFE reduces platelet deposition and neointimal hyperplasia in arteriovenous grafts.

  1998cited by this paper
• Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and αvβ3 Integrins

  1998cited by this paper
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

  1998cited by this paper
• Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.

  1998cited by this paper
• Comparative in‐vitro validation of eight first- and second‐generation quantitative coronary angiography systems

  1997cited by this paper
• Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation.

  1997cited by this paper
• Selective αvβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury1

  1997cited by this paper
• Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis.

  1995cited by this paper
• Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit.

  1995cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper
• Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group.

  1990cited by this paper
• Coronary Morphologic andClinical Determinants ofProcedural OutcomeWith Angioplasty forMultivessel Coronary Disease Implications forPatient Selection

  1990cited by this paper

• The use of glycoprotein IIb/IIIa inhibitors in elective PCI - A systematic review and meta-analysis of randomised trials.

  2025cites this paper
• Comparison of Clinical Outcomes among Various Percutaneous Coronary Intervention Strategies for Small Coronary Artery Disease.

  2023cites this paper
• Integrin ß1 polymorphisms and bleeding risk after coronary artery stenting

  2019cites this paper
• Prozedurbedingte Blutungen bei elektiven perkutanen Koronarinterventionen

  2018cites this paper
• Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.

  2016cites this paper
• Phospholipid Polymer Grafted Highly Cross-Linked UHMWPE

  2016cites this paper
• Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis.

  2016cites this paper
• Highly lubricated polymer interfaces for advanced artificial hip joints through biomimetic design

  2015cites this paper
• Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age

  2014cites this paper
• Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.

  2014cites this paper
• Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2014cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2013cites this paper
• Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease

  2013cites this paper
• Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?

  2013cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2013cites this paper
• Prognostic Value of Access and Non–Access Sites Bleeding After Percutaneous Coronary Intervention

  2013cites this paper
• Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy.

  2013cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention

  2013cites this paper
• Polymers for Artificial Joints

  2013cites this paper
• on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions the American College of Cardiology Foundation/American Heart Association Task Force 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A Report of

  2012cites this paper
• Cardiovascular Angiography and Interventions Association Task Force on Practice Guidelines and the Society for Report of the American College of Cardiology Foundation/American Heart 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A

  2012cites this paper
• Contribution au développement de recouvrements à base de simili-téflon et de polysaccharide pour les stents

  2012cites this paper
• Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

  2012cites this paper
• Evidence-Based Clinical Practice Guidelines American College of Chest Physicians and Prevention of Thrombosis, 9th ed: Antiplatelet Drugs : Antithrombotic Therapy

  2012cites this paper
• Stenting in Acute STEMI Intervention.

  2012cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary

  2012cites this paper
• ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES

  2012cites this paper
• Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• P2Y12 Antagonists in Acute Coronary Syndrome: In Whom Should They Be Started, and When?

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines.

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• the Society for Cardiovascular Angiography and Interventions Foundation/American Heart Association Task Force on Practice Guidelines and Executive Summary : A Report of the American College of Cardiology 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:

  2011cites this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

  2011cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2010cites this paper
• ISAR--a story of trials with impact on practice.

  2010cites this paper
• Treatment of small coronary arteries with a paclitaxel-coated balloon catheter

  2010cites this paper
• Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis

  2010cites this paper
• Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention

  2010cites this paper
• Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial

  2009cites this paper
• Cytochrome P 450 2 C 19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

  2009cites this paper
• Effekte von Rapamycin auf die Expression von Arteriosklerose- und Restenose- assoziierten Genen in humanen vaskulären glatten Muskelzellen

  2008cites this paper
• Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.

  2008cites this paper
• Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions.

  2008cites this paper
• Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.

  2008cites this paper
• Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

  2008cites this paper
• Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials

  2008cites this paper
• The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Antithrombotic Therapy: American College The Perioperative Management of

  2008cites this paper
• Perioperatives Management der antithrombotischen Therapie: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8. Auflage)

  2008cites this paper
• Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation.

  2007cites this paper
• Oral antiplatelet therapy for percutaneous coronary revascularization

  2007cites this paper
• Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions

  2007cites this paper
• Pharmacological antithrombotic adjuncts to percutaneous coronary intervention

  2007cites this paper
• Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices?

  2006cites this paper
• Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough.

  2006cites this paper
• Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels.

  2006cites this paper
• Transmutation of metal at low energy in a confined plasma in water

  2006cites this paper
• Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention

  2006cites this paper
• Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.

  2006cites this paper
• Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals

  2006cites this paper
• Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

  2006cites this paper
• Author index

  2004cites this paper
• Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.

  2001cites this paper
• Bmc Cardiovascular Disorders Effects of Abciximab on Key Pattern of Human Coronary Restenosis in Vitro: Impact of the Si/mpl-ratio

  year unknowncites this paper